clove and Nervous-System-Diseases

The therapeutic effects and side effects of mefloquine in falciparum malaria were investigated in an open prospective trial involving 20 patients. None of them had a history of neurologic or psychiatric disorders. Mefloquine was given in a total dose of 1500 mg base. The cure rate was 100%, fever and parasitemia subsided within 3 days. Side effects were vomitus and nausea in 25% of the patients. No neurological or psychiatric disorders were observed. Mefloquine was shown to be a safe therapeutic agent in the dosage used. However, regular follow-up examinations should be done in short intervals because of the possibility of late neuropsychiatric side effects; the patients and their relatives should be informed about this fact.

Topics: Adolescent; Adult; Africa, Western; Animals; Female; Germany; Humans; Madagascar; Malaria; Male; Mefloquine; Mental Disorders; Nausea; Nervous System Diseases; Plasmodium falciparum; Prospective Studies; Travel; Uganda; Vomiting

Post-malaria neurological syndrome is a rare complication of malaria. Typically, it occurs in case of severe malaria. Here we report a case in a Malagasy patient presenting a non-severe Plasmodium falciparum malaria complicated by post-malaria neurological syndrome. The management of such a syndrome is radically different from non-severe malaria. No specific treatment is needed.

Topics: Adolescent; Humans; Madagascar; Malaria, Cerebral; Malaria, Falciparum; Male; Nervous System Diseases; Plasmodium falciparum; Syndrome

By examining the sera from 1,408 healthy individuals in all six provinces of Madagascar with ELISA methods, we were able to demonstrate a very high prevalence for cysticercosis: 18%. The serologic markers for cysticercosis among 1,132 patients with neurologic symptoms was even higher: 36%. Furthermore, of 241 patients with neurocysticercosis, 82% of the serums recognized, in Western Blot test, the 14-20 Kd "evolutivity proteins". Cysticercosis is thus highly implicated in the neurologic syndromes found in Madagascar. Only adequate prophylaxis will permit a reduction in the incidence of this disease.

Topics: Adolescent; Adult; Animals; Antibodies, Helminth; Child; Child, Preschool; Cysticercosis; Cysticercus; Enzyme-Linked Immunosorbent Assay; Female; Humans; Madagascar; Male; Nervous System Diseases

Human cysticercosis is linked to infection by the larval stage of Taenia solium: Cysticercus cellulosae and was identified in Madagascar since 1901. Neurocysticercosis constitute, when parasite is localized in cerebral vesicles, a disease with important neurologic symptoms: epilepsia, spasms... This disease would be diagnosed before parasite calcification and this diagnosis permit Praziquantel treatment indication, with good results in many cases. We have developed cysticercosis diagnosis permitting: stage definition of the disease: Elisa and Western Blot tests, therapeutic following by enzyme immunoassay capture of serum cysticercosis antigens. We have observed: disease prevalence of 18% proving high rate of circulating parasite, in the countries studies, significative variation of circulating antigens and/or antibodies, one month after one or two Praziquantel treatment, in 82% of 130 patients. This disease seems to be important in Madagascar in neurologic syndromes, but the solution of this problem would result in prophylactic and concerted actions by public health means.

Topics: Adolescent; Adult; Child; Child, Preschool; Cysticercosis; Female; Humans; Madagascar; Male; Nervous System Diseases

Topics: Child; Child, Preschool; Humans; Infant; Madagascar; Malaria; Nervous System Diseases